L Brands (NYSE: LB) reported Q4 EPS of $1.89, $0.09 better than the analyst estimate of $1.80. Revenue for the quarter came in at $4.07 billion versus the consensus estimate of $4.03 billion. L Brands sees Q1 2015 EPS of $0.50-$0.55, versus the consensus of $0.62. L Brands sees FY2015 EPS of $3.45-$3.65, versus the consensus of $3.83.On Wednesday shares of L Brands, Inc. (NYSE:LB) closed at $92.47. Company’s sales growth for last 5 years was 3.60% and EPS growth for next 5 years is recorded as 11.78%.
On 23 February, Aruba Networks, Inc. (NASDAQ:ARUN) announced that Karl Soderlund, vice president of worldwide channels and alliances, and Jim Harold, vice president of North America channels, have been named to the prestigious list of the 2015 CRN Channel Chiefs Aruba Networks, Inc. (NASDAQ:ARUN) in last trading activity advanced 21.00% to close at $22.24. Company weekly performance is 21.07% while its quarterly performance stands at 18.17%. Aruba Networks, Inc. (NASDAQ:ARUN) is -6.95% away from its 52 week high.
On 23 February, Gigamon Inc. (NYSE: GIMO), announced that Chief Marketing Officer Peter Finter has been named to the prestigious list of the 2015 CRN Channel Chiefs. On last trading day Gigamon Inc. (NYSE:GIMO) advanced 0.20% to close at $20.09. Its volatility for the week is 3.32% while volatility for the month is 3.94%. GIMO’s sales growth for past 5 years was 38.00% and its EPS growth for past 5 years was -34.70%. Gigamon Inc. (NYSE:GIMO) monthly performance is 28.70%.
Comstock Resources, Inc. (NYSE:CRK) announced that it intends to offer $700 million in aggregate principal amount of senior secured notes due 2020 in a private offering, subject to market and other conditions. Comstock Resources Inc. (NYSE:CRK) has 7.50% insider ownership. In last trading activity company’s stock closed at $5.89.
Gilead Sciences, Inc. (NASDAQ:GILD) announced results from a preclinical study conducted in collaboration with researchers at Beth Israel Deaconess Medical Center evaluating a proprietary investigational oral toll-like receptor 7 (TLR7) agonist and analogue of GS-9620 as part of an HIV eradication strategy. On last trading day Gilead Sciences Inc. (NASDAQ:GILD) decreased -0.26% to close at $104.43. Its volatility for the week is 1.43% while volatility for the month is 2.31%. GILD’s sales growth for past 5 years was 28.80% and its EPS growth for past 5 years was 39.10%. Gilead Sciences Inc. (NASDAQ:GILD) monthly performance is -2.50%.